Skadden is representing Watson Pharmaceuticals, Inc. in connection with the antitrust aspects of its $5.6 billion acquisition of Actavis Group, announced on April 25.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Skadden is representing Watson Pharmaceuticals, Inc. in connection with the antitrust aspects of its $5.6 billion acquisition of Actavis Group, announced on April 25.